Pharmaceutical Supply chain Risk Assessment During COVID-19 Epidemic.

Area of Science:

• Supply Chain Management
• Pharmaceutical Industry
• Risk Assessment

Background:

• The COVID-19 pandemic significantly disrupted global health product supply chains.
• Increased risks within the pharmaceutical supply chain (PSC) necessitate robust assessment and mitigation strategies.

Purpose of the Study:

• To propose a novel approach for evaluating and addressing pharmaceutical supply chain risks.
• To identify the best mitigation strategies for the pharmaceutical industry in Tunisia during the COVID-19 pandemic.

Main Methods:

• A 2-Tuple ARAS-BWM approach was developed, integrating ARAS and BWM methods within a linguistic 2-Tuple framework.
• This method was applied to evaluate risks and determine optimal mitigation strategies in Tunisia's pharmaceutical sector.

Main Results:

• The primary risk identified in the pharmaceutical supply chain was related to supply and suppliers.
• The most effective mitigation strategy identified was focused on reducing overall risk.

Conclusions:

• The 2-Tuple ARAS-BWM approach provides an effective framework for pharmaceutical supply chain risk assessment and mitigation.
• Addressing supply and supplier vulnerabilities is critical for enhancing pharmaceutical supply chain resilience during global health crises.